Temsirolimus is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors.
For this indication, competent medicine agencies globally authorize below treatments:
25 - 25 mg
From 25 To 25 mg once every 7 day(s)
The recommended dose of temsirolimus for advanced RCC is 25 mg administered by intravenous infusion over a 30- to 60-minute period once a week.
Treatment of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy. If a suspected reaction is not manageable with dose delays, then temsirolimus may be reduced by 5 mg/week decrements.
Treatment of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy according to the guidelines in the following tables. If a suspected reaction is not manageable with dose delays and/or optimal medical therapy, then the dose of temsirolimus should be reduced according to the dose reduction table below.
Dose reduction levels:
|Dose reduction level||Starting dose 175 mg||Continuing dosea 75 mg|
|-1||75 mg||50 mg|
|-2||50 mg||25 mg|
a In the MCL clinical trial, up to two dose level reductions were allowed per patient.
Temsirolimus dose modifications based on weekly ANC and platelet counts:
|ANC||Platelets||Dose of temsirolimus|
|≥1,0 × 109/l||≥50 × 109/l||100% of planned dose|
|<1,0 × 109/l||<50 × 109/l||Holda|
a Upon recovery to ANC ≥1.0 × 109/l (1000 cells/mm³) and platelets to ≥50 × 109/l (50,000 cells/mm³), the doses should be modified to the next lower dose level according to the table above. If the patient cannot maintain ANC >1.0 × 109/l and platelets >50 × 109/l on the new dose reduction level, then the next lower dose should be given once the counts have recovered.
Abbreviation: ANC = absolute neutrophil count.
Patients should be given intravenous diphenhydramine 25 mg to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus.
Intravenous infusion over a 30- to 60-minute period.